A combination of molecular analysis of m6A genes might be valuable to identify a worse outcome in HCC patients who had neither been classified as “poor risk” because of the presence of mutated TERT (27), nor better survival outcome conferred by ARID1A mutations (28, 29), particularly in the TP53 wild-type HCC patients. Here, TERT is linked to hepatocellular carcinoma.